AI and ML Enhance ECG Interpretation

By Michael Awood

September 22, 2023

We’ve shown how AI and ML help diagnose and manage heart problems. New research has recently shown that a new ML model can improve ECG data interpretation, reducing misdiagnosis and optimizing patient monitoring data.

A further step is to look at monitoring and early disease detection while patients are being monitored within the home space. This is something our recent insight article has touched on.

By using traditional signal processing and ML, this model can overcome challenges caused by noisy data. They evaluated it using real-world single-lead ECG data from acutely ill patients receiving care at home as part of a ‘home hospital’ program. The model showed excellent performance, with a sensitivity of 98%, a specificity of 100%, an accuracy of 98%, a positive predictive value of 100%, and a negative predictive value of 93%.

It was effective in interpreting telemetry feeds for acutely ill patients. The current systems can detect atrial fibrillation with 92% accuracy and paroxysmal supraventricular tachycardia with 93% accuracy. However, the new ML algorithm could enhance arrhythmia identification.

The ML model can monitor chronically ill patients during medication changes or diagnose hidden arrhythmia. It could form the basis of a system that consistently monitors cardiac health through arrhythmia detection.

The study evaluated a single-lead ECG hybrid ML algorithm using data from acutely ill patients within a ‘home hospital’ programme. It shows the potential of AI and ML to enhance healthcare delivery and patient outcomes, particularly in cardiology. Investigating the impact of long-term arrhythmia burden on health outcomes is crucial for future research.

Reference url

Recent Posts

Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adult NF1 Patients

By HEOR Staff Writer

November 7, 2025

European Commission Approves Koselugo for Adult NF1 Patients The European Commission has granted approval for Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, to treat symptomatic, inoperable plexiform neurofibromas in adult patients with neu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss Potential
Are you wondering about the latest eloralintide obesity treatment options? Eloralintide, a selective amylin receptor agonist, has shown promising results in managing obesity. In a recent phase 2 trial, it led to significant weight loss of up to 20% over 48 weeks in adults with obesity or overweig...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Efficiency

By HEOR Staff Writer

November 5, 2025

UK Clinical Trial Reforms Slash Approval Times UK Clinical Trial Reforms have accelerated clinical trial approvals, reducing average times from 91 days to 41 days through risk-proportionate changes at the Medicines and Healthcare produ...